BRAF-targeted therapy and immune responses to melanoma
Oncoimmunology, 2013•Taylor & Francis
Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the
treatment of advanced malignant melanoma. We have recently elucidated a role for host CC
chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in
mice, supporting the therapeutic potential of combining BRAF inhibitors with
immunotherapy.
treatment of advanced malignant melanoma. We have recently elucidated a role for host CC
chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in
mice, supporting the therapeutic potential of combining BRAF inhibitors with
immunotherapy.
Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.
Taylor & Francis Online